{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:50:05Z","timestamp":1778766605734,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1053\/j.seminhematol.2026.03.007","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:00:47Z","timestamp":1773457247000},"page":"370-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Roadmap for developing MRD as an early endpoint for drug approval in lymphoma"],"prefix":"10.1053","volume":"62","author":[{"given":"Jordan S.","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine E.D.","family":"Chamuleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-5625","authenticated-orcid":false,"given":"Ash A.","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.007_bib0001","doi-asserted-by":"crossref","first-page":"7597","DOI":"10.1182\/blood-2024-208810","article-title":"Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2023","volume":"144","author":"Luo","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.007_bib0002","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.007_bib0003","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.007_bib0004","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.03.007_bib0005","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.2023023789","article-title":"The current landscape of frontline large B-cell lymphoma trials","volume":"145","author":"Qualls","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.03.007_bib0006","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1101\/2024.04.01.24305158","article-title":"Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials","volume":"3","author":"Sherry","year":"2024","journal-title":"BMJ Oncol"},{"key":"10.1053\/j.seminhematol.2026.03.007_bib0008","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2023.04.001","article-title":"Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020)","volume":"159","author":"Ribeiro","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1053\/j.seminhematol.2026.03.007_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103711","article-title":"Validity of event-free survival as a surrogate endpoint in haematological malignancy: review of the literature and health technology assessments","volume":"175","author":"Assouline","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.007_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2023022269","article-title":"What clinicians should know about surrogate end points in hematologic malignancies","volume":"144","author":"Bommier","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.007_bib0011","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.007_bib0012","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1182\/bloodadvances.2020002690","article-title":"End-of-treatment PET\/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA","volume":"5","author":"Kostakoglu","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.007_bib0013","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood-2023-180007","article-title":"End-of-treatment response assessment after frontline therapy for aggressive B-cell lymphoma: landmark comparison of a singular PET\/CT scan versus ultrasensitive circulating tumor DNA","volume":"142","author":"Roschewski","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.007_bib0014","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.03.007_bib0015","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/s41416-020-0805-y","article-title":"Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review","volume":"122","author":"Belin","year":"2020","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.007_bib0016","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.007_bib0017","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.03.007_bib0018","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.03.007_bib0019","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.03.007_bib0020","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/OP-24-00648","article-title":"Cell-free DNA in hematologic malignancies","volume":"20","author":"Schroers-Martin","year":"2024","journal-title":"JCO Oncol Pr"},{"key":"10.1053\/j.seminhematol.2026.03.007_bib0021","unstructured":"US Department of Health and Human Services. Hematologic malignancies: Regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment: Guidance for industry. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. January 2020."},{"key":"10.1053\/j.seminhematol.2026.03.007_bib0022","unstructured":"US Department of Health and Human Services. Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development: Guidance for industry. Oncology Center of Excellence. November 2024."},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.007_bib0023","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2024-200290","article-title":"High-risk subgroups and MRD: an updated analysis of the phase 3 ECHO trial of acalabrutinib with bendamustine\/rituximab in previously untreated mantle cell lymphoma","volume":"144","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.007_bib0024","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.23.00838","article-title":"Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM study","volume":"42","author":"Pott","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1053\/j.seminhematol.2026.03.007_bib0025","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO-25-00690","article-title":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2026.03.007_bib0026","article-title":"Advancing CAR T-cell therapy: evidence-based trial design for chimeric antigen receptor T-cell therapy in oncology","author":"Mahat","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.007_bib0027","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/hematology.2021000312","article-title":"Does MRD have a role in the management of iNHL?","volume":"2021","author":"Giudice","year":"2021","journal-title":"Hematology"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.03.007_bib0028","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.007_bib0029","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2023-187759","article-title":"Optimizing circulating tumor DNA limits of detection for DLBCL during first line therapy","volume":"142","author":"Goldstein","year":"2023","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.03.007_bib0030","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1200\/JCO.19.00014","article-title":"Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"37","author":"Wang","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2026.03.007_bib0031","doi-asserted-by":"crossref","first-page":"TPS7085","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7085","article-title":"ALPHA3: a pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy","volume":"43","author":"Westin","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2026.03.007_bib0032","doi-asserted-by":"crossref","first-page":"TPS7095","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7095","article-title":"Sequencing-guided chemotherapy optimization using real-time evaluation in newly diagnosed DLBCL with circulating tumor DNA: SHORTEN-ctDNA (NCT06693830)","volume":"43","author":"Cherng","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.007_bib0033","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2024-206512","article-title":"High rates of undetectable MRD by phased-seq on interim and end of treatment timepoints in untreated advanced stage chl treated with pembrolizumab\u202f+\u202fAVD","volume":"144","author":"Lynch","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.007_bib0034","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2026.03.007_bib0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-138889","article-title":"Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.03.007_bib0036","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-01534","article-title":"Remission assessment by circulating tumor DNA in large B-cell lymphoma","author":"Roschewski","year":"2025","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1053\/j.seminhematol.2026.03.007_bib0037","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2026.03.007_bib0038","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2025.43.16_suppl.7000","article-title":"Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"S3","key":"10.1053\/j.seminhematol.2026.03.007_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70093_6","article-title":"6 | Feasibility of ctdna and pet guided therapy in untreated dlbcl. Preliminary results of the Sakk 38\/19 phase ii trial","volume":"43","author":"Stathis","year":"2025","journal-title":"Hematol Oncol"},{"issue":"27","key":"10.1053\/j.seminhematol.2026.03.007_bib0040","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.007_bib0041","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.007_bib0042","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2024-199813","volume":"144","author":"Stepan","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.03.007_bib0043","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"7996","key":"10.1053\/j.seminhematol.2026.03.007_bib0044","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.03.007_bib0045","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.2024027355","article-title":"A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA","volume":"146","author":"Pirosa","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.007_bib0046","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2024-201877","article-title":"Ultrasensitive circulating tumor DNA MRD status predicts treatment failure & complements PET\/CT throughout treatment for early and advanced stage classic Hodgkin lymphoma","volume":"144","author":"Boegeholz","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.03.007_bib0047","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2352-3026(20)30291-X","article-title":"Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group","volume":"7","author":"Le Gouill","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.007_bib0048","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.23.00899","article-title":"Predictive value of minimal residual disease for efficacy of rituximab maintenance in mantle cell lymphoma: results from the European mantle cell lymphoma elderly trial","volume":"42","author":"Hoster","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.007_bib0049","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the Nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.03.007_bib0050","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 2","key":"10.1053\/j.seminhematol.2026.03.007_bib0051","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-212973","volume":"144","author":"Fenske","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.03.007_bib0052","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.007_bib0053","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2024-204495","article-title":"MRD-driven time-limited therapy of acalabrutinib and lenalidomide plus rituximab (ALR) or obinutuzumab (ALO) in patients with treatment-na\u00efve mantle cell lymphoma: phase 2 trial outcomes with MRD and cfDNA analyses","volume":"144","author":"Ruan","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.03.007_bib0054","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41375-022-01803-x","article-title":"Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT","volume":"37","author":"Jim\u00e9nez-Ubieto","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.007_bib0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fern\u00e1ndez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.007_bib0056","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood-2023-187116","article-title":"Longitudinal noninvasive surveillance & fragmentomic characterization of follicular lymphoma","volume":"142","author":"Schroers-Martin","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.03.007_bib0057","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2023-189824","article-title":"Phased variants allow robust profiling of circulating tumor DNA in untreated follicular lymphomas","volume":"142","author":"Nagy","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.03.007_bib0058","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:06:24Z","timestamp":1778727984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0037196326000211"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.007","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roadmap for developing MRD as an early endpoint for drug approval in lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}